Form 4: Clover Health CEO Sells Shares for Tax Obligations

Clover Health CEO Andrew Toy disposed of 242,580 Class A Common Stock shares to cover tax obligations related to RSU vesting.

Summary

• Andrew Toy, Chief Executive Officer and Director of Clover Health Investments, Corp., disposed of 242,580 shares of Class A Common Stock.
• The transaction occurred on October 15, 2025, at a price of $2.8 per share.
• These shares were automatically withheld to cover tax obligations arising from the vesting of 25% of his restricted stock units (RSUs).
• Following this transaction, Andrew Toy beneficially owns 9,922,982 shares of Class A Common Stock.
• The remaining RSUs will vest quarterly in equal installments of 6.25% until the final vesting date of October 15, 2028, contingent on his continued service.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, non-discretionary 'sell to cover' for tax purposes related to RSU vesting, which is a common occurrence for executives and does not indicate a change in sentiment towards the company.

Positives

• The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is a common and expected event for executive compensation plans and does not indicate a lack of confidence in the company.
• Andrew Toy retains substantial beneficial ownership of 9,922,982 shares of Class A Common Stock after the transaction.

Negatives

• The disposal of shares, even for tax purposes, results in a slight reduction in the CEO's direct ownership.

Risks

• No specific new risks are identified in this filing beyond the inherent risks associated with executive compensation structures involving equity awards and their tax implications.

Future Outlook

Remaining restricted stock units (RSUs) granted to Andrew Toy will vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to his continued service.

Industry Context

This transaction is a routine insider 'sell to cover' event, common across all publicly traded companies where executive compensation includes restricted stock units. It does not provide specific insights into broader industry trends for the healthcare or insurance sectors.

Comparison to Industry Standards

• This is a standard 'sell to cover' transaction for RSU vesting, a common practice for executives in public companies across various industries. It aligns with typical compensation structures and tax compliance procedures observed in comparable companies.

Stakeholder Impact

• Shareholders: The transaction represents a minor, routine reduction in the CEO's direct shareholding, which is a common occurrence with RSU vesting and tax withholding. It is unlikely to have a significant impact on shareholder value or perception.
• Employees: No direct impact on employees is mentioned or implied by this filing.

Next Steps

• Remaining restricted stock units will vest quarterly in 6.25% installments, with the final vesting on October 15, 2028, contingent on continued service.

Key Dates

Recommendation

The filing details a routine, non-discretionary 'sell to cover' transaction by the CEO to satisfy tax obligations upon RSU vesting. This is a common event for executives and does not reflect a change in the company's fundamentals or the CEO's confidence. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

Clover Health, CLOV, Andrew Toy, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, CEO, Director